C38 UNDERSTANDING THERAPEUTICS IN IPF: Cc-90001, A Second Generation Jun N-Terminal Kinase (JNK) Inhibitor For The Treatment Of Idiopathic Pulmonary Fibrosis

C38 UNDERSTANDING THERAPEUTICS IN IPF: Cc-90001, A Second Generation Jun N-Terminal Kinase (JNK) Inhibitor For The Treatment Of Idiopathic Pulmonary Fibrosis

[...]we have developed CC-90001, a JNK1-biased inhibitor that was evaluated for JNK-inhibitory activity and antifibrotic efficacy in multiple cell-based and in vivo models. In a house dust mite model of lung fibrosis, both CC-90001 and CC-930 treatment decreased multiple measures of lung collagen an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Hauptverfasser: Bennett, B, Blease, K, Ye, Y, Azaryan, A, Ramirez-Valle, F, Ceres, R, Horan, G, Schafer, P, Van Der Velden, J L, Janssen-Heininger, Y M W
Format: Artikel
Sprache:eng
Schlagworte:
Pulmonary fibrosis
Rodents
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[...]we have developed CC-90001, a JNK1-biased inhibitor that was evaluated for JNK-inhibitory activity and antifibrotic efficacy in multiple cell-based and in vivo models. In a house dust mite model of lung fibrosis, both CC-90001 and CC-930 treatment decreased multiple measures of lung collagen and reduced disease induced increases in a-SMA to nearly baseline levels.
ISSN:1073-449X
1535-4970